Citric Acid
A naturally occurring tricarboxylic acid widely used in pharmaceutical formulations as an acidulant, buffering agent, antioxidant, and chelating agent. It is also used as a urinary alkalinizer in oral solutions to dissolve uric acid and cystine kidney stones. As a component of anticoagulant solutions, it binds calcium to prevent blood clotting during storage.
Moleküler Ağırlık
192,1200 g/mol
LogP
-1,70
TPSA
132,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D Yapı
Cite this structure
Embed this structure
SMILES
O=C(O)CC(O)(CC(=O)O)C(=O)O
InChI
InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
Molecular Formula
C6H8O7
HBD / HBA
4 / 7
Döndürülebilir Bağlar
5
Ağır Atomlar
13
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A naturally occurring tricarboxylic acid widely used in pharmaceutical formulations as an acidulant, buffering agent, antioxidant, and chelating agent. It is also used as a urinary alkalinizer in oral solutions to dissolve uric acid and cystine kidney stones. As a component of anticoagulant solutions, it binds calcium to prevent blood clotting during storage.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Citric Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1261. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 311. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="citric-acid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/citric-acid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/citric-acid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/citric-acid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="citric-acid"></drugfyi-drug>